Lonza Group Ltd, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Thibault Boutherin from Morgan Stanley upgraded the rating on the stock to a Buy and gave it a CHF650.00 price target.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Thibault Boutherin has given his Buy rating due to a combination of factors that highlight Lonza Group Ltd’s potential for growth and value. The company is expected to continue its strong business trends into 2026, with projections of low-teens organic growth and margin expansion. This positive outlook is supported by the attractive valuation of Lonza’s stock, which is currently near the lower end of its historical range, presenting a compelling entry point for investors.
Additionally, macroeconomic factors such as potential lower interest rates and a shift in investment portfolios towards healthcare are anticipated to further bolster Lonza’s stock performance. The announcement of 2026 guidance in January is seen as a catalyst that could reinforce market confidence and support a re-rating of the shares. Overall, Boutherin’s analysis suggests that Lonza is well-positioned to capitalize on these favorable conditions, offering significant upside potential for investors.
Based on the recent corporate insider activity of 11 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of LONN in relation to earlier this year.